Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.caplinpoint.net | |
Market Cap | 6,141.90 Cr. | |
Enterprise Value(EV) | 5,651.83 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 49.55 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 16.32 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 33.63 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 247.65 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 3.27 | Calculated using Price: 808.85 |
Dividend Yield | 0.25 | Period Ending 2022-03 |
No. of Shares Subscribed | 7.59 Cr. | 75,933,746 Shares |
FaceValue | 2 | |
About Caplin Point Laboratories Ltd. | ||
Caplin Point is the mid-sized company in India's pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility. |
1 Day |
|
+4.03% |
1 Week |
|
+6.91% |
1 Month |
|
+17.94% |
3 Month |
|
+22.35% |
6 Month |
|
+8.50% |
1 Year |
|
+6.24% |
2 Year |
|
+35.13% |
5 Year |
|
+68.44% |
10 Year |
|
+6519.07% |
9 years | 2014-06 | 2015-06 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 53.24 | 55.78 | 43.13 | 54.97 | 49.43 | 37.14 | 29.58 | 25.65 | 24.71 | |
Return on Capital Employed (%) | 68.99 | 71.11 | 55.41 | 69.03 | 64.08 | 45.59 | 33.35 | 28.82 | 28.77 | |
Return on Assets (%) | 16.48 | 20.12 | 18.46 | 30.54 | 33.68 | 28.41 | 23.02 | 20.20 | 19.94 |
Particulars | 10 years | 2014-06 Rs. Cr. | 2015-06 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
Shh. Funds | 62 | 93 | 128 | 225 | 364 | 633 | 948 | 1,186 | 1,484 | 1,880 | |
Non Curr. Liab. | 10 | 10 | 14 | 20 | 28 | 23 | 25 | 17 | 13 | 2 | |
Curr. Liab. | 108 | 125 | 125 | 113 | 109 | 86 | 144 | 143 | 208 | 268 | |
Minority Int. | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 18 | 26 | 27 | |
Equity & Liab. | 180 | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,730 | 2,178 | |
Non Curr. Assets | 131 | 147 | 149 | 179 | 196 | 249 | 303 | 349 | 432 | 623 | |
Curr. Assets | 49 | 82 | 119 | 179 | 304 | 494 | 823 | 1,015 | 1,298 | 1,554 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 180 | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,730 | 2,178 |
Particulars | 10 years | 2014-06 Rs. Cr. | 2015-06 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. TTM |
Net Sales | 173 | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | |
Other Income | 4 | 3 | 4 | 10 | 13 | 19 | 41 | 28 | 39 | 56 | |
Total Income | 177 | 255 | 242 | 412 | 553 | 668 | 905 | 1,089 | 1,308 | 1,523 | |
Total Expenditure | -137 | -192 | -175 | -277 | -345 | -417 | -603 | -737 | -875 | -1,026 | |
PBIDT | 40 | 63 | 68 | 135 | 208 | 251 | 301 | 352 | 433 | 497 | |
Interest | -1 | -1 | 0 | -1 | -1 | -1 | 0 | -2 | -1 | -1 | |
Depreciation | -4 | -8 | -7 | -13 | -19 | -23 | -32 | -37 | -47 | -45 | |
Taxation | -10 | -12 | -14 | -25 | -44 | -50 | -54 | -62 | -77 | -74 | |
Exceptional Items | |||||||||||
PAT | 26 | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | |
Minority Interest | 0 | 0 | 0 | 0 | 0 | -9 | -9 | -1 | |||
Share Associate | 0 | ||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 26 | 41 | 46 | 96 | 145 | 177 | 215 | 242 | 300 | 376 | |
Adjusted EPS | 3 | 5 | 6 | 13 | 19 | 23 | 28 | 32 | 40 | 50 |
Particulars | 10 years | 2013-06 Rs. Cr. | 2014-06 Rs. Cr. | 2015-06 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 32 | 60 | 50 | 42 | 68 | 66 | 83 | 45 | 269 | 337 | |
Cash Fr. Inv. | -45 | -44 | -23 | -6 | -36 | -69 | -100 | -55 | -29 | -271 | |
Cash Fr. Finan. | -1 | -6 | -9 | -14 | -7 | -12 | 90 | 80 | -24 | -41 | |
Net Change | -15 | 10 | 19 | 23 | 25 | -14 | 73 | 70 | 215 | 25 | |
Cash & Cash Eqvt | 17 | 27 | 45 | 68 | 91 | 77 | 151 | 221 | 436 | 461 |
Thu, 08 Jun 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate This is to inform that mentioned share certificate has been reported as lost by the shareholder of the Company. |
Fri, 02 Jun 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript In continuation of our letter dated May 22 2023 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the transcript of the presentation made on Saturday May 27 2023 on audited Financial Results (Consolidated and Standalone) of the Company for the quarter and year ended March 31 2023 is available on the Companys website |
Thu, 01 Jun 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release US FDA inspection completed at Caplin Steriles Injectable site at Gummidipoondi |
Thu, 08 Jun 2023 |
|
|
|
|
|